The Department of Medical Microbiology has teamed up with an International Registry of Men with Prostate Cancer known as IRONMAN. The main goal of this registry is to improve outcomes in men with advanced prostate cancer around the world.
The Registry will have an international cohort of a minimum of 5,000 men with advanced prostate cancer, including men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and M0/M1 Castrate-Resistant Prostate Cancer (CRPC).
The Kenyan team includes Principal Investigator Dr. Charles Waihenya, Co-Principal Investigators Prof. Muthoni Musibi, Dr. Andrew Gachii, Dr. Samuel Gathere and Chair of the Department Dr. Marianne Mureithi, Molecular Biology PhD Candidate and Instructor George Ichoho among others. The team of Medical Doctors and Scientists aim to recruit a minimum of 150 study participants. The Department will act as the regional biorepository site for all samples collected which will aid in the identification and validation of molecular phenotypes of the disease that predict response and resistance to specific therapeutics. The study will run until 2029 and the selected sites are Kenyatta National Hospital (KNH) and MP Shah Hospital.
Patients who enrol in this study will have detailed information collected from them for a minimum of five years to monitor overall survival, comorbidities, changes in cancer treatment, clinically significant adverse events and Patient-Reported Outcome Measures (PROMs). The cohort aims to gain a better understanding in the variation of care and treatment of advanced prostate cancer globally.